Passed by the House February 10, 2006 Yeas 93   FRANK CHOPP ________________________________________ Speaker of the House of Representatives Passed by the Senate March 8, 2006 Yeas 43   BRAD OWEN ________________________________________ President of the Senate | I, Richard Nafziger, Chief Clerk of the House of Representatives of the State of Washington, do hereby certify that the attached is SUBSTITUTE HOUSE BILL 2640 as passed by the House of Representatives and the Senate on the dates hereon set forth. RICHARD NAFZIGER ________________________________________ Chief Clerk | |
Approved March 23, 2006. CHRISTINE GREGOIRE ________________________________________ Governor of the State of Washington | March 23, 2006 - 10:15 a.m. Secretary of State State of Washington |
State of Washington | 59th Legislature | 2006 Regular Session |
READ FIRST TIME 2/7/06.
AN ACT Relating to biotechnology product and medical device manufacturing tax incentives; amending RCW 82.32.600; adding a new section to chapter 82.32 RCW; adding a new chapter to Title 82 RCW; providing an effective date; and providing an expiration date.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON:
NEW SECTION. Sec. 1 The legislature finds that the state's
economy is increasingly dependent on the expansion of knowledge-based
sectors, including the life sciences. The legislature also finds that
commercial enterprises in the life sciences create high-wage,
high-skilled jobs that are part of the state's effort to encourage
economic diversification and stability. However, the legislature also
finds that commercial life sciences businesses, particularly in
biotechnology product and medical device manufacturing, incur
significant costs associated with capital infrastructure and job
training often years before a product is licensed for marketing or a
facility is licensed for manufacturing by governmental agencies in the
United States and abroad. The legislature also finds that current
state tax policy discourages the growth of these companies in two ways:
(1) Washington state's higher rate of taxation compared with other
states and nations encourages the export of intellectual property and
commercial operations out of Washington; and (2) taxing these
businesses before facilities, or products produced therein, are
licensed for marketing by regulatory agencies.
The legislature further finds that targeted tax incentives may
encourage the formation, expansion, and retention of commercial
operations within the life sciences sector. The legislature also finds
that tax incentives should be subject to the same rigorous requirements
for efficiency and accountability as are other expenditure programs,
and that tax incentives should therefore be focused to provide the
greatest possible return on the state's investment.
For these reasons, the legislature hereby establishes a tax
deferral program for commercial manufacturing facilities in this
sector. The legislature declares that these limited programs serve the
vital public purposes of incenting expenditures in commercial life
science operations and the development of employment opportunities in
this state. The legislature further declares its intent to create a
contract within the meaning of Article I, section 23 of the state
Constitution as to those businesses that make capital investments in
consideration of the tax deferral program established in this chapter.
NEW SECTION. Sec. 2 Unless the context clearly requires
otherwise, the definitions in this section apply throughout this
chapter.
(1) "Applicant" means a person applying for a tax deferral under
this chapter.
(2) "Biotechnology" means a technology based on the science of
biology, microbiology, molecular biology, cellular biology,
biochemistry, or biophysics, or any combination of these, and includes,
but is not limited to, recombinant DNA techniques, genetics and genetic
engineering, cell fusion techniques, and new bioprocesses, using living
organisms, or parts of organisms.
(3) "Biotechnology product" means any virus, therapeutic serum,
antibody, protein, toxin, antitoxin, vaccine, blood, blood component or
derivative, allergenic product, or analogous product produced through
the application of biotechnology that is used in the prevention,
treatment, or cure of diseases or injuries to humans.
(4) "Department" means the department of revenue.
(5)(a) "Eligible investment project" means an investment in
qualified buildings or qualified machinery and equipment, including
labor and services rendered in the planning, installation, and
construction of the project.
(b) The lessor or owner of a qualified building is not eligible for
a deferral unless:
(i) The underlying ownership of the buildings, machinery, and
equipment vests exclusively in the same person; or
(ii)(A) The lessor by written contract agrees to pass the economic
benefit of the deferral to the lessee;
(B) The lessee that receives the economic benefit of the deferral
agrees in writing with the department to complete the annual survey
required under section 8 of this act; and
(C) The economic benefit of the deferral passed to the lessee is no
less than the amount of tax deferred by the lessor and is evidenced by
written documentation of any type of payment, credit, or other
financial arrangement between the lessor or owner of the qualified
building and the lessee.
(6)(a) "Initiation of construction" means the date that a building
permit is issued under the building code adopted under RCW 19.27.031
for:
(i) Construction of the qualified building, if the underlying
ownership of the building vests exclusively with the person receiving
the economic benefit of the deferral;
(ii) Construction of the qualified building, if the economic
benefits of the deferral are passed to a lessee as provided in
subsection (5)(b)(ii)(A) of this section; or
(iii) Tenant improvements for a qualified building, if the economic
benefits of the deferral are passed to a lessee as provided in
subsection (5)(b)(ii)(A) of this section.
(b) "Initiation of construction" does not include soil testing,
site clearing and grading, site preparation, or any other related
activities that are initiated before the issuance of a building permit
for the construction of the foundation of the building.
(c) If the investment project is a phased project, "initiation of
construction" shall apply separately to each phase.
(7) "Manufacturing" has the meaning provided in RCW 82.04.120.
(8) "Medical device" means an instrument, apparatus, implement,
machine, contrivance, implant, in vitro reagent, or other similar or
related article, including any component, part, or accessory, that is
designed or developed and:
(a) Recognized in the national formulary, or the United States
pharmacopeia, or any supplement to them;
(b) Intended for use in the diagnosis of disease, or in the cure,
mitigation, treatment, or prevention of disease or other conditions in
human beings or other animals; or
(c) Intended to affect the structure or any function of the body of
man or other animals, and which does not achieve any of its primary
intended purposes through chemical action within or on the body of man
or other animals and which is not dependent upon being metabolized for
the achievement of any of its principal intended purposes.
(9) "Person" has the meaning provided in RCW 82.04.030.
(10) "Qualified buildings" means construction of new structures,
and expansion or renovation of existing structures for the purpose of
increasing floor space or production capacity used for biotechnology
product manufacturing or medical device manufacturing activities,
including plant offices, commercial laboratories for process
development, quality assurance and quality control, and warehouses or
other facilities for the storage of raw material or finished goods if
the facilities are an essential or an integral part of a factory,
plant, or laboratory used for biotechnology product manufacturing or
medical device manufacturing. If a building is used partly for
biotechnology product manufacturing or medical device manufacturing and
partly for other purposes, the applicable tax deferral shall be
determined by apportionment of the costs of construction under rules
adopted by the department.
(11) "Qualified machinery and equipment" means all new industrial
and research fixtures, equipment, and support facilities that are an
integral and necessary part of a biotechnology product manufacturing or
medical device manufacturing operation. "Qualified machinery and
equipment" includes: Computers; software; data processing equipment;
laboratory equipment; manufacturing components such as belts, pulleys,
shafts, and moving parts; molds, tools, and dies; operating structures;
and all equipment used to control or operate the machinery.
(12) "Recipient" means a person receiving a tax deferral under this
chapter.
NEW SECTION. Sec. 3 Application for deferral of taxes under this
chapter must be made and approved before initiation of the construction
of the investment project or acquisition of equipment or machinery.
The application shall be made to the department in a form and manner
prescribed by the department. The application shall contain
information regarding the location of the investment project, the
applicant's average employment in the state for the prior year,
estimated or actual new employment related to the project, estimated or
actual wages of employees related to the project, estimated or actual
costs, time schedules for completion and operation, and other
information required by the department. The department shall rule on
the application within sixty days.
NEW SECTION. Sec. 4 (1) The department shall issue a sales and
use tax deferral certificate for state and local sales and use taxes
due under chapters 82.08, 82.12, and 82.14 RCW for each eligible
investment project.
(2) No certificate may be issued for an investment project that has
already received a deferral under chapter 82.60 or 82.63 RCW or this
chapter.
(3) The department shall keep a running total of all deferrals
granted under this chapter during each fiscal biennium.
(4) This section expires January 1, 2017.
NEW SECTION. Sec. 5 (1) Except as provided in subsection (2) of
this section and section 8 of this act, taxes deferred under this
chapter need not be repaid.
(2)(a) If, on the basis of the survey under section 8 of this act
or other information, the department finds that an investment project
is used for purposes other than qualified biotechnology product
manufacturing or medical device manufacturing activities at any time
during the calendar year in which the eligible investment project is
certified by the department as having been operationally completed, or
at any time during any of the seven succeeding calendar years, a
portion of deferred taxes shall be immediately due and payable
according to the following schedule:
Year in which use occurs | % of deferred taxes due |
1 | 100% |
2 | 87.5% |
3 | 75% |
4 | 62.5% |
5 | 50% |
6 | 37.5% |
7 | 25% |
8 | 12.5% |
NEW SECTION. Sec. 6 Chapter 82.32 RCW applies to the
administration of this chapter.
NEW SECTION. Sec. 7 Applications received by the department
under this chapter are not confidential and are subject to disclosure.
NEW SECTION. Sec. 8 A new section is added to chapter 82.32 RCW
to read as follows:
(1) For the purposes of this section, "biotechnology product and
medical device business tax incentive" or "tax incentive" means the
sales and use tax deferrals under chapter 82.-- RCW (sections 1 through
7 of this act).
(2) The legislature finds that accountability and effectiveness are
important aspects of setting tax policy. In order to make policy
choices regarding the best use of limited state resources, the
legislature needs information to evaluate whether the stated goals of
legislation were achieved.
(3) The goals of the biotechnology product and medical device
business tax incentives are to:
(a) Encourage the creation, expansion, and retention of commercial
biotechnology product and medical device manufacturing operations and
related job opportunities; and
(b) Fully mature the life sciences industry by creating a
sustainable commercial sector.
(4)(a) A person who receives the benefit of a biotechnology product
and medical device business tax incentive shall provide an annual
survey to the department. The survey is due by March 31st following
any year in which a tax incentive is claimed or used. The survey shall
not include names of employees. The survey shall include the amount of
the tax incentives claimed or used for the reporting year. The survey
shall also include the following information for employment positions
in Washington:
(i) The number of total employment positions;
(ii) Full-time, part-time, and temporary employment positions as a
percent of total employment;
(iii) The number of employment positions according to the following
wage bands: Less than thirty thousand dollars; thirty thousand dollars
or greater, but less than sixty thousand dollars; and sixty thousand
dollars or greater. A wage band containing fewer than three
individuals may be combined with another wage band; and
(iv) The number of employment positions that have employer-provided
medical, dental, and retirement benefits, by each of the wage bands.
(b) The department may request additional information necessary to
measure the results of the tax incentive, to be submitted at the same
time as the survey.
(c) All information collected under this subsection, except the
amount of the tax incentive claimed or used, is deemed taxpayer
information under RCW 82.32.330 and is not disclosable. Information on
the amount of tax incentive claimed or used is not subject to the
confidentiality provisions of RCW 82.32.330 and may be disclosed to the
public upon request.
(5) The department shall use the information from this section to
prepare summary descriptive statistics by category. No fewer than
three taxpayers shall be included in any category. The department
shall report these statistics to the legislature each year by September
1st.
(6) If a person fails to submit an annual survey under subsection
(4)(a) of this section by the due date of the survey, the department
shall declare 12.5 percent of the deferred tax from the date of
deferral to be immediately due and payable. Excise taxes payable under
this subsection are subject to interest but not penalties, as provided
under this chapter. This information is not subject to the
confidentiality provisions of RCW 82.32.330 and may be disclosed to the
public upon request.
(7) The department shall use the information to study the tax
incentive specified in subsection (1) of this section. The department
shall report to the legislature by December 1, 2009, and December 1,
2015. The reports shall measure the number of new biotechnology
product and medical device manufacturing facilities established in
Washington, the amount of investment in biotechnology product and
medical device manufacturing facilities, the number of facilities and
investment by firms that utilized the biotechnology product and medical
device business tax incentive, the number of biotechnology product and
medical device manufacturing jobs in these facilities, the wages and
benefits paid for biotechnology product and medical device
manufacturing jobs, and the wages and benefits of biotechnology product
and medical device manufacturing jobs compared to wages and benefits of
other manufacturing jobs and jobs in other economic sectors.
Sec.9 RCW 82.32.600 and 2005 c 514 s 1002 are each amended to
read as follows:
(1) Persons required to file surveys under RCW 82.04.4452 must
electronically file with the department all surveys, returns, and any
other forms or information the department requires in an electronic
format as provided or approved by the department, unless the department
grants relief under subsection (2) of this section. As used in this
section, "returns" has the same meaning as "return" in RCW 82.32.050.
(2) Upon request, the department may relieve a person of the
obligations in subsection (1) of this section if the person's taxes
have been reduced a cumulative total of less than one thousand dollars
from all of the credits, exemptions, or preferential business and
occupation tax rates, for which a person is required to file an annual
survey under RCW 82.04.4452, 82.32.535, 82.32.545, 82.32.570,
82.32.560, 82.60.070, ((or)) 82.63.020, or section 8 of this act.
(3) Persons who no longer qualify for relief under subsection (2)
of this section will be notified in writing by the department and must
comply with subsection (1) of this section by the date provided in the
notice.
(4) Any survey, return, or any other form or information required
to be filed in an electronic format under subsection (1) of this
section is not filed until received by the department in an electronic
format.
NEW SECTION. Sec. 10 This act takes effect July 1, 2006.
NEW SECTION. Sec. 11 Sections 1 through 7 of this act constitute
a new chapter in Title
NEW SECTION. Sec. 12 If any provision of this act or its
application to any person or circumstance is held invalid, the
remainder of the act or the application of the provision to other
persons or circumstances is not affected.